Breaking News: (Nasdaq: NCEL) Hires World-Renowned Pioneer To Scientific Advisory Board

NewcelX Ltd. (Nasdaq: NCEL) tops Wednesday's watchlist

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Breaking News: (Nasdaq: NCEL) Hires World-Renowned Pioneer To Scientific Advisory Board Consider Starting Your Own Research On (NCEL)... [ Company Website ] | [ Corporate Communications ] *Get Our Updates Faster—Tap Here To Receive SMS Alerts* July 8th Greetings, Friend! NewcelX Ltd. (Nasdaq: NCEL) tops Wednesday's watchlist and could start attracting some serious buzz. Why? How about the breaking news they just dropped this morning? Take a look: NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials Dr. Ricordi to support advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals ZURICH, July 08, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biotechnology company developing regenerative cell therapies for type 1 diabetes and other serious diseases, today announced the appointment of Camillo Ricordi, M.D., F.N.A.I., to its Scientific Advisory Board. Dr. Ricordi is internationally recognized as one of the world's foremost authorities in diabetes cure-focused research, beta-cell replacement, and cellular transplantation. With more than 1,250 scientific publications, over 64,000 citations, an h-index of 123, and numerous pioneering contributions to the field of islet transplantation, Dr. Ricordi has played a central role in advancing cell-based approaches for type 1 diabetes worldwide. "Dr. Ricordi's appointment to our Scientific Advisory Board represents an important validation of our scientific strategy and our commitment to advancing potentially transformative therapies for patients living with type 1 diabetes," said Ronen Twito, Chief Executive Officer and Chairman of NewcelX. "His unparalleled expertise and global reputation in diabetes research will be invaluable as we continue to advance our clinical development programs and strengthen our position within the diabetes and transplantation communities." ... "I believe regenerative medicine and cell-based therapies have the potential to fundamentally transform the treatment paradigm for type 1 diabetes," said Dr. Camillo Ricordi. "The combination of stem cell-derived islet replacement and targeted immune modulation represents one of the most promising approaches currently being pursued in the field. I am pleased to join NewcelX and look forward to supporting the advancement of its clinical strategy and its collaboration with Eledon Pharmaceuticals toward a potential functional cure for T1D." As a member of the Scientific Advisory Board, Dr. Ricordi will actively advise and support the clinical translation of NewcelX's biologic replacement strategy and regenerative medicine platform. Read the full article here. Don't forget. NCEL is a low float idea. With fewer than 3Mn shares in its float, the potential for heightened volatility may be significant for NCEL on a daily basis. Take a moment to review our initial (Nasdaq: NCEL) report below and consider this profile for your watchlist. ----- There is a type of company that arrives without drawing attention to itself. It moves through regulatory checkpoints, builds out its science, assembles the right advisors, and one day finds itself standing at the threshold of a First-In-Human clinical trial, pursuing one of the few genuinely differentiated approaches to treating a disease that has resisted a functional cure for over a century. On May 27th, 2026, this company filed a Pre-IND briefing package with the U.S. FDA to support a proposed First-In-Human trial of its lead stem cell-derived islet product, in combination with tegoprubart, developed by Eledon Pharmaceuticals. Furthermore, a successful Type B meeting with the FDA was recently held during the final week of June. NewcelX Ltd. (Nasdaq: NCEL) is the product of a merger finalized on October 30th, 2025, between NLS Pharmaceutics Ltd. and Kadimastem Ltd, a cell therapy company. The deal united Kadimastem's validated human pluripotent stem cell platform with a focus on translational regenerative medicine and cell therapy development across metabolic disease and immune-modulated indications. The combined company relisted on Nasdaq under NCEL. The Underlying Science Deserves Attention Type 1 Diabetes is a condition in which the body's own immune system destroys the insulin-producing beta cells in the pancreas. The approach NewcelX is advancing with NCEL-101 is fundamentally different: replace the destroyed islet cells using scalable, off-the-shelf, stem cell-derived islets, and pair those transplanted cells with targeted immune protection. The collaborative framework with Eledon, specifically tegoprubart, evaluated in over 100 transplant recipients across multiple FDA-cleared IND studies, is what makes the immune protection component clinically credible. The company maintains access to a $25Mn Equity Line of Credit and is substantially debt-free. With a market capitalization hovering around $21Mn (7/7/26), the gap between this company's current chart valuation and the scale of the unmet medical need it is targeting may be one of the more striking disconnects in the clinical-stage biopharma space right now. Two Platforms, One Clinical Mission NewcelX Ltd. (Nasdaq: NCEL) is a clinical-stage regenerative medicine company incorporated in Switzerland and headquartered in Zurich, with research and development operations in Ness Ziona, Israel. The company's operating model is built around an allogeneic, off-the-shelf cell therapy manufacturing strategy Rather than producing patient-specific therapies, NewcelX is designing its pipeline to be manufactured from renewable pluripotent cell banks, frozen, and shipped globally, an approach that supports broad patient access and standardized production at scale. “We believe our scalable stem cell-derived islet platform, combined with targeted immune protection, represents one of the few differentiated approaches aimed at a potential functional cure for Type 1 Diabetes.” — Ronen Twito, Executive Chairman & CEO, NewcelX Ltd. | April 30th, 2026 Cell Therapy for T1D - Structural Scale, Unsolved Problem The global cell therapy market represents one of the most structurally significant long-cycle themes in heal-thcare. Unlike traditional pharmaceuticals that interact with biochemistry, cell therapies aim to replace or restore biological function at the cellular level, an approach that, in diseases like Type 1 Diabetes, offers the possibility of functional resolution rather than lifelong symptom management. Global T1D Patients - 9.5Mn Children with T1D - 1.8Mn U.S. Annual Diabetes Cost - $640Bn / year Curative Standard of Care - None Currently Exists What gives this market context particular strategic weight right now is the regulatory environment. The FDA has publicly signaled a commitment to streamlining the IND process for Type 1 Diabetes innovations, a point referenced directly by CEO Ronen Twito in the company's May 2026 Pre-IND announcement. The combination of scalable stem cell-derived islets with a calcineurin inhibitor-free immune protection regimen represents a small cohort of programs globally. Recent NCEL Milestones May 27th, 2026 - FDA Pre-IND Package Submitted For NCEL-101 NewcelX filed its Pre-IND briefing package with the FDA to support the proposed First-In-Human trial of NCEL-101 combined with tegoprubart. A successful Type B pre-IND meeting with the FDA just happened at the end of June 2026. March 9th, 2026 - Strategic Collaboration Announced With Eledon Pharmaceuticals Formal collaborative research agreement to advance combination strategies pairing NCEL-101 with tegoprubart (AT-1501). Designed to support durable, immune-protected islet replacement and a potential functional cure for Type 1 Diabetes. January 5th, 2026 - Dr. Julien Boisdron (CMO of Roche) Appointed To Scientific Advisory Board Diabetes specialist with 20+ years of global pharmaceutical leadership, currently CMO of a major Swiss multinational pharma company, joins the SAB to advise on NCEL-101 translational strategy, patient adoption, and commercialization frameworks. October 31st, 2025 - Merger Completed As NCEL Takes A Spin On The Nasdaq NLS Pharmaceutics x Kadimastem merger closed; combined company relisted as NewcelX Ltd. (NCEL) on the Nasdaq. Consider Starting Your Own Research On (NCEL)... [ Company Website ] | [ Corporate Communications ] These 7 Potential Catalysts Put (Nasdaq: NCEL) At the Top of Our Watchlist #1. FDA Engagement The successful Type B pre-IND meeting with the FDA just happened at the end of June 2026 and puts NCEL in direct regulatory dialogue at a moment when the agency has publicly signaled its commitment to streamlining the IND pathway for Type 1 Diabetes cell therapy innovations. #2. Tight Float With approximately 2.61Mn shares in its float, NCEL carries one of the tighter share structures in the clinical-stage biotech space, a factor that becomes relevant when catalysts arrive and market interest accelerates. #3. Validated Science The human pluripotent stem cell platform underpinning the company's NCEL-101 program has been validated through years of GMP manufacturing development, prior FDA interactions, and preclinical work accumulated during the AstroRx® ALS program, all now applied directly to the flagship diabetes asset. #4. Strategic Alliance The collaborative research agreement between NCEL and Eledon Pharmaceuticals integrates tegoprubart, a next-generation anti-CD40L antibody with safety data from over 100 transplant recipients, into the immune protection layer of NCEL-101, meaningfully reducing a core technical risk in islet cell therapy. #5. Off-the-Shelf Model NCEL's allogeneic manufacturing strategy is designed for scalability and cost efficiency, a structural advantage over autologous approaches that require individualized production and cannot easily be standardized across large patient populations. #6. Bullish Technicals As of 1:00PM EST Tuesday, Barchart was reporting at least 9 triggered technical indicators across terms. Furthermore, one of those eight that were triggered was the website's composite "Trend Seeker" indicator. #7. Deep Advisory Bench The scientific advisory board assembled around NCEL includes Dr. Julien Boisdron (CMO at a major Swiss multinational pharma, 20+ years in diabetes care); Prof. Jeremy Shefner, MD, PhD (CMO at Barrow Neurological Institute, co-founder of NEALS ALS consortium, 200+ peer-reviewed papers); and Prof. Tamir Ben-Hur, MD, PhD (neuroimmunology expert at Hadassah and Hebrew University). We Will Have All Eyes On NewcelX (Nasdaq: NCEL) Wednesday Morning. NewcelX Ltd. (Nasdaq: NCEL) is navigating the most consequential stretch of its existence. The merger that created it is less than a year old. Its lead program has just completed its Pre-IND submission to the FDA. A Type B meeting with regulators just happened at the end of June. The scientific advisory board has been built with purpose. The manufacturing partner is in place. The immune protection collaborator has clinical data from over 100 transplant recipients. What markets are watching is whether the company can convert that groundwork into a cleared IND and a path to First-In-Human data. The disease it is targeting affects 9.5Mn people globally. The current standard of care is a lifetime of daily management. The approach NewcelX is advancing goes further, it is aimed at the underlying biology. We're kicking off coverage on NewcelX Ltd. (Nasdaq: NCEL). Be on the lookout for updates coming soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. NewcelX Ltd (NCEL:US) previously changed their company name and symbols from NLS Pharmaceutics AG (NLSP:US) Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 07/07/2026 and ending on 07/08/2026 to publicly disseminate information about (NCEL:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty two thousand USD ("Funds"). These Funds were part of the seventeen thousand five hundred USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NCEL:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ncel-puvls/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice